Evidence Based Treatments of Alopecia Areata
DOI:
https://doi.org/10.48112/acmr.v3i4.42Keywords:
Androgenetic Alopecia, non-cicatricial alopecia, minoxidilAbstract
Abstract Views: 152
Androgenetic Alopecia (AGA) is considered as major non-cicatricial alopecia which causes progressive hair follicle miniaturization. To a large extent, a person's genetic makeup and hormonal environment determine whether or not their terminal scalp hairs will be transformed into vellus hairs. AGA becomes more common and commoner as people get older. AGA is a progressive disorder characterized by a shortening of the anagen phase and maintenance of the telogen phase. Females with AGA tend to see more diffuse hair loss over the head, while males with AGA tend to experience thinning near the vertex. The gold standard treatments for AGA are minoxidil (used topically) and finasteride (an oral 5α-reductase inhibitor type II inhibitor) and they are the only medications accepted by the Food and Drug Administration (FDA) to date. The success of existing therapy for AGA is frequently questioned, making the discovery of new therapeutics for this illness of critical importance. In an effort to slow the disease's course and boost its outcomes, this article will examine the causes and diagnostic tools used to identify AGA.
References
Alves R. Androgenetic alopecia: a review and emerging treatments. Clin Res Dermatol Open Access. 2017;4(04):1-13.
Gan DC, Sinclair RD. Prevalence of male and female pattern hair loss in Maryborough. The journal of investigative dermatology Symposium proceedings. 2005;10(3):184-9.
Blume-Peytavi U, Blumeyer A, Tosti A, Finner A, Marmol V, Trakatelli M, et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. The British journal of dermatology. 2011;164(1):5-15.
Jang WS, Son IP, Yeo IK, Park KY, Li K, Kim BJ, et al. The annual changes of clinical manifestation of androgenetic alopecia clinic in korean males and females: a outpatient-based study. Ann Dermatol. 2013;25(2):181-8.
Alves R, Grimalt R. Androgenetic alopecia in adolescents. Pract Pediatr Dermatol. 2016:187-96.
Zhao J, Harada N, Okajima K. Dihydrotestosterone inhibits hair growth in mice by inhibiting insulin-like growth factor-I production in dermal papillae. Growth Horm IGF Res. 2011;21(5):260-7. doi: 10.1016/j.ghir.2011.07.003.
Mubki T, Rudnicka L, Olszewska M, Shapiro J. Evaluation and diagnosis of the hair loss patient: part I. History and clinical examination. J Am Acad Dermatol. 2014;71(3):415.e1-415.e15. doi: 10.1016/j.jaad.2014.04.070.
Norwood OT. Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg. 2001;27(1):53-4.
Blumeyer A, Tosti A, Messenger A, Reygagne P, Del Marmol V, Spuls PI, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges. 2011;9 Suppl 6:S1-57. doi: 10.1111/j.1610-0379.2011.07802.x.
Torres F. Androgenetic, diffuse and senescent alopecia in men: practical evaluation and management. Curr Probl Dermatol. 2015;47:33-44. doi: 10.1159/000369403.
Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest. 2001;107(4):409-17. doi: 10.1172/JCI11317.
Kaliyadan F, Nambiar A, Vijayaraghavan S. Androgenetic alopecia: an update. Indian J Dermatol Venereol Leprol. 2013;79(5):613-25. doi: 10.4103/0378-6323.116730.
Bazzano GS, Terezakis N, Galen W. Topical tretinoin for hair growth promotion. J Am Acad Dermatol. 1986;15(4 Pt 2):880-3, 890-3. doi: 10.1016/s0190-9622(86)80024-x.
Kelly Y, Blanco A, Tosti A. Androgenetic Alopecia: An Update of Treatment Options. Drugs. 2016;76(14):1349-64. doi: 10.1007/s40265-016-0629-5.
Eun HC, Kwon OS, Yeon JH, Shin HS, Kim BY, Ro BI, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63(2):252-8.
Tsunemi Y, Irisawa R, Yoshiie H, Brotherton B, Ito H, Tsuboi R, et al. Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia. J Dermatol. 2016;43(9):1051-8. doi: 10.1111/1346-8138.13310.
Coneac A, Muresan A, Orasan MS. Antiandrogenic Therapy with Ciproterone Acetate in Female Patients Who Suffer from Both Androgenetic Alopecia and Acne Vulgaris. Clujul Med. 1957;87(4):226-34.
Moftah N, Moftah N, Abd-Elaziz G, Ahmed N, Hamed Y, Ghannam B, et al. Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation. J Eur Acad Dermatol Venereol. 2013;27(6):686-93. doi: 10.1111/j.1468-3083.2012.04535.x.
Gupta AK, Foley KA. A Critical Assessment of the Evidence for Low-Level Laser Therapy in the Treatment of Hair Loss. Dermatol Surg. 2017;43(2):188-197. doi: 10.1097/DSS.0000000000000904.
Avci P, Gupta GK, Clark J, Wikonkal N, Hamblin MR. Low-level laser (light) therapy (LLLT) for treatment of hair loss. Lasers Surg Med. 2014;46(2):144-51. doi: 10.1002/lsm.22170.
Avram MR, Rogers NE. The use of low-level light for hair growth: part I. J Cosmet Laser Ther. 2009;11(2):110-7. doi: 10.1080/14764170902842531.
Gilhar A, Keren A, Paus R. A new humanized mouse model for alopecia areata. J Investig Dermatol Symp Proc. 2013;16(1):S37-8. doi: 10.1038/jidsymp.2013.11.
Hordinsky M, Kaplan DH. Low-dose interleukin 2 to reverse alopecia areata. JAMA Dermatol. 2014;150(7):696-7. doi: 10.1001/jamadermatol.2014.510.
Tojo G, Fujimura T, Kawano M, Ogasawara K, Kambayashi Y, Furudate S, et al. Comparison of interleukin-17-producing cells in different clinical types of alopecia areata. Dermatology. 2013;227(1):78-82.
Lew B-L, Cho H-R, Haw S, Kim H-J, Chung J-H, Sim W-Y. Association between IL17A/IL17RA gene polymorphisms and susceptibility to alopecia areata in the Korean population. Ann Dermatol. 2012;24(1):61-5.
Darwin E, Hirt PA, Fertig R, Doliner B, Delcanto G, Jimenez JJ. Alopecia Areata: Review of Epidemiology, Clinical Features, Pathogenesis, and New Treatment Options. Int J Trichology. 2018;10(2):51-60. doi: 10.4103/ijt.ijt_99_17.
Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043-9. doi: 10.1038/nm.3645.
d’Ovidio R, Roberto M. Limited effectiveness of platelet-rich plasma treatment on chronic severe alopecia areata. Hair Ther Transplant. 2014; 4: 116.
Chikhalkar S, Jerajani H, Madke B. Evaluation of utility of phenol in alopecia areata. Int J Trichology. 2013;5(4):179-84. doi: 10.4103/0974-7753.130390.
Wikramanayake TC, Villasante AC, Mauro LM, Perez CI, Schachner LA, Jimenez JJ. Prevention and treatment of alopecia areata with quercetin in the C3H/HeJ mouse model. Cell Stress Chaperones. 2012;17(2):267-74. doi: 10.1007/s12192-011-0305-3.
Lee SH, Yoon J, Shin SH, Zahoor M, Kim HJ, Park PJ, et al. Valproic acid induces hair regeneration in murine model and activates alkaline phosphatase activity in human dermal papilla cells. PLoS One. 2012;7(4):e34152. doi: 10.1371/journal.pone.0034152.
Kim HM, Lim YY, Kim MY, Son IP, Kim DH, Park SR, et al. Inhibitory effect of tianeptine on catagen induction in alopecia areata-like lesions induced by ultrasonic wave stress in mice. Clin Exp Dermatol. 2013;38(7):758-67. doi: 10.1111/ced.12047.
Lim Y, Kim S, Kim H, Li K, Kim M, Park KC, et al. Potential relationship between the canonical Wnt signalling pathway and expression of the vitamin D receptor in alopecia. Clin Exp Dermatol. 2014;39(3):368-75.
Duncan FJ, Silva KA, Johnson CJ, King BL, Szatkiewicz JP, Kamdar SP, et al. Endogenous retinoids in the pathogenesis of alopecia areata. J Invest Dermatol. 2013;133(2):334-43. doi: 10.1038/jid.2012.344.
Deepak SH, Shwetha S. Scalp roller therapy in resistant alopecia areata. J Cutan Aesthet Surg. 2014;7(1):61-2. doi: 10.4103/0974-2077.129988.
Tanaka Y, Aso T, Ono J, Hosoi R, Kaneko T. Androgenetic Alopecia Treatment in Asian Men. J Clin Aesthet Dermatol. 2018;11(7):32-35.
Flores A, Schell J, Krall AS, Jelinek D, Miranda M, Grigorian M, et al. Lactate dehydrogenase activity drives hair follicle stem cell activation. Nat Cell Biol. 2017;19(9):1017-26.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Advances in Clinical Medical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
OAI-PMH 
